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Translational Medicine, London, UKBackground & Aims: Intrahepatic cholestasis of pregnancy (ICP) fetal cardiac phenotype characterized by increased NT-proBNP
is associated with an increased risk of stillbirth. This study aimed
to assess the relationship between bile acid concentrations and
fetal cardiac dysfunction in patients with ICP who were or were
not treated with ursodeoxycholic acid (UDCA).
Methods: Bile acid profiles and NT-proBNP, a marker of ven-
tricular dysfunction, were assayed in umbilical venous serum
from 15 controls and 76 ICP cases (36 untreated, 40 UDCA-
treated). Fetal electrocardiogram traces were obtained from 43
controls and 48 ICP cases (26 untreated, 22 UDCA-treated). PR
interval length and heart rate variability (HRV) parameters were
measured in 2 behavioral states (quiet and active sleep).
Results: In untreated ICP, fetal total serum bile acid (TSBA)
concentrations (r = 0.49, p = 0.019), hydrophobicity index (r =
0.20, p = 0.039), glycocholate concentrations (r = 0.56, p = 0.007)
and taurocholate concentrations (r = 0.44, p = 0.039) positively
correlated with fetal NT-proBNP. Maternal TSBA (r = 0.40, p =
0.026) and alanine aminotransferase (r = 0.40, p = 0.046) also
positively correlated with fetal NT-proBNP. There were no sig-
nificant correlations between maternal or fetal serum bile acid
concentrations and fetal HRV parameters or NT-proBNP con-
centrations in the UDCA-treated cohort. Fetal PR interval length
positively correlated with maternal TSBA in untreated (r = 0.46,
p = 0.027) and UDCA-treated ICP (r = 0.54, p = 0.026). Measures of
HRV in active sleep and quiet sleep were significantly higher in
untreated ICP cases than controls. HRV values in UDCA-treated
cases did not differ from controls.
Conclusions: Elevated fetal and maternal serum bile acid con-
centrations in untreated ICP are associated with an abnormalwords: Pregnancy; Female; Ursodeoxycholic acid; Intrahepatic cholestasis of
gnancy; Cholic acid; Stillbirth; Heart rate; Bile; Ventricular dysfunction.
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Lay summary: The risk of stillbirth in intrahepatic cholestasis of
pregnancy (ICP) is linked to the level of bile acids in the mother
which are thought to disrupt the baby’s heart rhythm. We found
that babies of women with untreated ICP have abnormally
functioning hearts compared to those without ICP, and the de-
gree of abnormality is closely linked to the level of harmful bile
acids in the mother and baby’s blood. Babies of women with ICP
who received treatment with the drug UDCA do not have the
same level of abnormality in their hearts, suggesting that UDCA
could be a beneficial treatment in some ICP cases, although
further clinical trials are needed to confirm this.
© 2021 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Intrahepatic cholestasis of pregnancy (ICP), the most common
gestational liver disease, is diagnosed in women with pruritus
and elevated maternal total serum bile acid (TSBA) concentra-
tions.1,2 ICP is associated with adverse pregnancy outcomes;
when maternal TSBA concentrations were >−40 lmol/L the like-
lihood of spontaneous preterm birth, prolonged neonatal unit
admission and fetal asphyxia were significantly increased in a
prospective Swedish cohort, and stillbirth was also increased in a
UK cohort.2,3 More recently, the prevalence of stillbirth was
shown to increase from 0.28% to 3.44% in singleton pregnancies
with maternal TSBA concentrations of >−100 lmol/L; the preva-
lence of stillbirth in the control cohort of this study was found to
be 0.31%.4
The mechanism of ICP-associated stillbirth is unknown, with
post-mortem findings indicating that infants are appropriately
grown.5 However, there is evidence of fetal cardiac dysfunction
in pregnancies complicated by ICP, with speculation of a sudden
arrhythmic event causing fetal demise.6 Echocardiography has21 vol. 74 j 1087–1096
Research Article DILI, Autoimmune, Cholestatic and Genetic Diseasesdemonstrated fetal atrial flutter and supraventricular tachycardia
in ICP and cardiotocography (CTG) monitoring has detected
bradycardia preceding a stillbirth.7–10 In women with both
ursodeoxycholic acid (UDCA)-treated and untreated ICP, fetal left
ventricular (LV) function is impaired, as evidenced by increased
LV myocardial performance index, increased myocardial tissue
velocities, reduced LV global strain rate and increased iso-
volumetric contraction and relaxation times via echocardiogra-
phy, all of which are more pronounced in severe ICP.11–15 In
addition, concentrations of N-terminal pro-B-type natriuretic
peptide (NT-proBNP) and cardiac troponin I, markers used to
diagnose heart failure and LV systolic dysfunction, are increased
in fetal umbilical venous blood from ICP pregnancies.15,16 There is
echocardiography evidence of increased fetal PR interval length
in both UDCA-treated and untreated ICP which is associated with
disease severity.17–19 Although there is currently no evidence to
suggest ICP prolongs fetal QTc interval length, maternal QTc in-
terval prolongation has been reported in womenwith mild ICP.20
There are no conclusive data about the effect of ICP on fetal heart
rate variability (fHRV), an established indicator of fetal auto-
nomic nervous system function and wellbeing in utero, or the
effect of UDCA treatment on this parameter.21 Fetal heart rate
activity exists in 4 different behavioral states (1F-4F), defined
based on specific heart rate patterns, eye and body move-
ments.22 The fetus spends the majority of the time in 1F and 2F,
thought to resemble non-REM (quiet) sleep and REM (active
sleep), respectively.23 Analyzing fHRV in the context of behav-
ioral state is necessary in order to differentiate between normal
and abnormal activity. For example, state 1F is associated with
reduced HRV and movement compared to state 2F.22Participant cohort n
Controls 43
Untreated severe ICP 10
UDCA-treated severe ICP 6
Untreated mild ICP 16



























39 participants from Nottingham City Hospital
33 participants from St. Thomas’ Hospital
12 participants from Queen Charlotte’s Hospital
9 participants from St. Richard's Hospital
Fig. 1. Flowchart depicting numbers of participants in each analyzed cohort
1088 Journal of Hepatology 20UDCA marginally reduces maternal pruritus and most studies
have shown improved concentrations of maternal and fetal TSBA
in ICP.24,25 UDCA has a demonstrably lower bile acid hydropho-
bicity index (HI), a measure associated with bile acid-induced
intra- and extracellular cytotoxicity.26,27 It has a protective ef-
fect in in vitro fetal heart models, attenuating taurocholic acid
(TCA)-induced slowing of ventricular conduction velocity in
neonatal rat hearts and inhibiting TCA-induced conduction ab-
normalities in human fetal and adult heart models.28–30 The
impact of UDCA on human fetal cardiac dysfunction in vivo,
however, is yet to be fully established. There have been reports of
fetal demise and CTG abnormalities occurring in UDCA-treated
pregnancies and fetuses of UDCA-treated cohorts have dis-
played LV dysfunction and prolonged mechanical PR interval
length,10,12,17,30–32 however most studies do not adjust for
severity of hypercholanaemia.
We aimed to establish whether untreated severe ICP causes a
fetal cardiac phenotype that predisposes to potentially fatal
cardiac arrhythmia using measurement of fetal cardiac time in-
terval (CTI), fHRV and NT pro-BNP concentrations in the umbil-
ical venous blood. We also aimed to evaluate the impact of UDCA
treatment on fetal cardiac parameters.
Patients and methods
Recruitment for umbilical venous blood assays
Umbilical venous blood was collected from ICP participants ±
UDCA treatment and matched controls after informed consent
from St. Thomas’ and Queen Charlotte’s Hospitals, UK, between
September 2009 and January 2019 (ethical approval REC








Untreated severe ICP 15
UDCA-treated severe ICP 25
Untreated mild ICP 21
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For umbilical venous blood analysis:
30 participants from St. Thomas’ Hospital
61 participants from Queen Charlotte’s Hospital
and the sites they were recruited from.
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participants were also recruited from the PITCHES trial (n = 14)
(EudraCT number: 2014-004478-41).25
ICP was diagnosed in women with pruritus and non-fasting
serum TSBA concentrations >−10 lmol/L. Peak maternal TSBA
concentrations taken during pregnancy were used to classify
women as having mild (10–39 lmol/L) or severe (>−40 lmol/L)
ICP. Women treated with UDCA (500–2,500 mg per day) were
analyzed separately to untreated cases. Women recruited as
controls had uncomplicated pregnancies with no symptoms of
ICP and no diagnosis of ICP in previous pregnancies. Maternal
and fetal demographic and delivery details for these participants
are summarized in Table S1.
Umbilical venous blood was collected immediately after de-
livery in plain vacutainers and centrifuged for 15 minutes at
3,500 rpm; umbilical serum was frozen within 30 minutes at
-80C. NT-proBNP was assayed using a human proBNP ELISA kit
(Raybiotech, GA, USA) as per manufacturer’s instructions. Indi-
vidual bile acids were measured by ultra-performance liquid
chromatography tandem mass spectrometry (UPLC-MS/MS). The
HI of fetal bile acids in each serum sample was calculated using
the molar fraction and the previously reported hydrophobicity of
individual bile acids by Heuman et al..26
Recruitment for ECG recording
Prospective cohorts of women with ICP or uncomplicated preg-
nancy who were >−20 weeks of gestation were recruited after
informed consent from Nottingham City Hospital between
October 2007 and January 2011 and St. Thomas’, Queen Char-
lotte’s and St. Richard’s Hospitals in the UK between January
2015 and June 2019 (REC numbers 08/H0707/21 and 15/WM/
0017) (Fig. 1). Some participants were also recruited from the
PITCHES trial (n = 3).26 Although ethical permission was granted
to collect umbilical venous blood in women who underwent
electrocardiogram (ECG) recording, a separate cohort was
required due to the low number of women who gave both types
of sample. ICP was diagnosed as previously described. Maternal
TSBA concentrations were tested via enzymatic assay within 3
days of participation to obtain a measurement close to the time
of fetal ECG (fECG) recording. ICP cases treated with UDCA
(500–2,500 mg per day) at the time of fECG acquisition were
analyzed separately to untreated cases. Demographic and de-
livery details of participants are shown in Table S2.
ECG collection, data processing and analysis
The Monica AN24 (Monica Healthcare Limited, Nottingham, UK)
was used to obtain overnight fECG recordings as previously
described.33,34 ECG processing and analysis are described in the
supplementary methods.
Statistical analyses
Statistical analysis and figures were created using Stata IC v15.0
(Stata Corporation, TX, USA) and are described in the supple-
mentary methods. Initial investigation of differences between
laboratory, clinical and delivery details of women who had ECGs
or bile acid profile and NT-proBNP measurements was per-
formed via a Kruskal Wallis analysis of variance (ANOVA)
without pairwise multiple comparison tests after participants
were designated into control, untreated and UDCA-treated co-
horts of mild or severe ICP. p values of <0.05 were considered
statistically significant and data are presented as median [IQR] or
n (%).Journal of Hepatology 20Partial correlation analysis was used to investigate the
strength of association between fetal NT-proBNP concentra-
tion and fetal bile acid profiles or maternal TSBA, alanine
aminotransferase (ALT) and bilirubin concentrations in un-
treated and UDCA-treated ICP. Partial correlation analysis was
also used to investigate the strength of associations among
cardiac time intervals, HRV parameters and maternal TSBA
concentration at the time of ECG recording in untreated and
UDCA-treated ICP. Skewness and kurtosis tests confirmed all
continuous variables were abnormally distributed and were
therefore log-transformed (using natural logarithm) prior to
analysis. Correlations investigating fetal NT-proBNP concen-
trations were controlled for the covariates of mode of de-
livery, induction of labor, gestational age at delivery and fetal
sex. Correlations investigating fetal cardiac data were
controlled for the covariates of gestational age and fetal sex.
Correlations investigating maternal cardiac data were
controlled for the covariates of maternal BMI and maternal
age.
Fetal HRV data were separated by behavioral state; the small
sample size and lower likelihood of finding the fetus in behav-
ioral states 3F or 4F prevented the statistical analysis of these
data and they were therefore excluded.
Results
Clinical and demographic details of participants
Clinical and demographic details of participants are provided in
Tables S1 and S2. Participants with ICP had increased rates of
induced labor in both groups compared to controls with un-
complicated pregnancy, and infants from participants with se-
vere ICP, in whom fECG was collected, had increased neonatal
unit admission.
Maternal and fetal serum bile acid concentrations and fetal
bile acid HI are positively correlated with fetal NT-proBNP
concentrations
One-way ANOVA demonstrated significant differences in peak
maternal and fetal TSBA concentrations, and fetal NT-proBNP
concentrations at delivery between participant cohorts
(Fig. 2A-C). Multiple comparison tests indicated maternal and
fetal TSBA concentrations in severe ICP were significantly higher
than in controls (Fig. 2A and B). Similarly, fetal NT-proBNP con-
centrations were significantly higher in untreated severe ICP
than in controls (Fig. 2C).
One-way ANOVA of individual bile acids in umbilical venous
blood demonstrated significant differences in fetal TSBA and
individual bile acid concentrations between cohorts (Table S3).
There were significant positive correlations between fetal NT-
proBNP and HI of the fetal bile acids (Fig. 3A) and with con-
centrations of fetal TSBA, glycocholic acid (GCA) and TCA in the
untreated ICP cohort (Fig. 3B). No correlations were observed
between fetal NT-proBNP concentrations and fetal TSBA in the
UDCA-treated cohort (Fig. 3B).
Maternal peak TSBA and ALT concentrations are positively
correlated with fetal NT-proBNP concentrations
A significant positive partial correlation was observed between
fetal NT-proBNP and maternal concentrations of TSBA and ALT
when analyzing untreated ICP cases and controls together
(Fig. 4A and B). No correlation was found between fetal NT-






























































































































Fig. 2. Dot plots depicting TSBA and NT-proBNP concentrations. Controls
(n = 15), individuals with severe untreated ICP (n = 15), severe UDCA-treated
ICP (n = 25), mild untreated ICP (n = 21) or UDCA-treated mild ICP (n = 15).
(A) Peak maternal TSBA concentrations measured during pregnancy; (B) cor-
responding fetal TSBA concentrations measured using umbilical venous blood;
(C) fetal NT-proBNP concentrations measured using umbilical venous blood.
Analysis via Kruskal Wallis test with post-hoc Dunn's, *p <0.05, ***p <0.001,
****p <0.0001. ICP, intrahepatic cholestasis of pregnancy; NT-proBNP, N-ter-
minal pro-B-type natriuretic peptide; TSBA, total serum bile acid; UDCA,
ursodeoxycholic acid.
Research Article DILI, Autoimmune, Cholestatic and Genetic DiseasesAnalysis of untreated ICP cases demonstrated significant positive
correlations between fetal NT-proBNP and maternal TSBA and
ALT concentrations (Fig. 4C and E). No correlations were
observed in the UDCA-treated group (Fig. 4D and F).1090 Journal of Hepatology 20Maternal TSBA concentrations are positively correlated with
the prolongation of the fetal PR interval length, but not the
length of the QTc interval or QRS duration
One-way ANOVA demonstrated significant differences in fetal PR
interval length between cohorts (Table S4). Partial correlation
analysis demonstrated a significant positive correlation between
maternal TSBA and fetal PR interval length measurements when
analyzing untreated ICP cases and controls together (Fig. 5C).
Analysis of ICP cases demonstrated significant positive correla-
tions between maternal TSBA concentrations and fetal PR inter-
val length for both untreated and UDCA-treated cases (Fig. 5D
and E, respectively). No significant correlations with maternal
TSBA concentration were observed when analyzing fetal QTc
interval length or QRS duration (Fig. S2A and B, respectively).
There were no significant correlations between maternal TSBA
concentrations and maternal CTI (Fig. S3A-C).
Maternal TSBA concentrations positively correlated with fetal
heart rate variability
To investigate ICP-induced changes in fHRV, we performed time-
domain analysis on the RR intervals derived from fECGs of
women with untreated ICP. One-way ANOVA demonstrated sig-
nificant differences in root mean square of successive differences
(RMSSD) and standard deviation of normal to normal intervals
(SDNN) values in behavioral state 2F (Table S4).
Partial correlation analysis demonstrated a lack of correlation
between maternal TSBA concentrations and fetal RMSSD values
from behavioral state 1F (quiet sleep), while a significant positive
correlation was observed in values from behavioral state 2F
(active sleep) (Fig. 6A and C, respectively). Positive correlations
were also observed between maternal TSBA concentrations and
fetal SDNN values in both behavioral states (Fig. 6B and D,
respectively).
When all untreated cases were compared using one-way
ANOVA, there was a significant increase of RMSSD values in
behavioral state 2F (active sleep) (9.6 [8.8–11.3] vs. 8.7 [7.6–9.6]
ms, p = 0.028, Fig. 6G) and SDNN values in behavioral state 1F
(quiet sleep) (11.0 [9.5–14.9] vs. 7.9 [5.1–9.7] ms, p = 0.013,
Fig. 6F) and active sleep 2F (25.4 [21.0–32.4] vs. 18.2 [14.7–25.7]
ms, p = 0.003, Fig. 6H). UDCA treatment was associated with a
significant reduction in RMSSD in behavioral state 2F cases (8.5
[7.4–9.7] ms, p = 0.030, Fig. 6G), and there was a non-significant
attenuation of the ICP-associated increase in SDNN values in
UDCA-treated cases (Fig. 6F and H). There were no significant
correlations between maternal TSBA concentrations and
maternal HRV values (Fig. S3D-F).
Discussion
In this study, we have demonstrated that untreated ICP is asso-
ciated with a fetal cardiac phenotype that positively correlates
with fetal and maternal serum bile acid concentrations (sum-
marized in Table S5). We found that the fetuses of women taking
UDCA treatment did not have the same dysfunctional cardiac
phenotype for most parameters, suggesting that UDCA may be
cardioprotective.
The fetal cardiac phenotype observed in untreated ICP
constituted, in part, an elevated fetal NT-proBNP concentration
in umbilical venous blood, which is an indicator of fetal distress,
tachy- and bradyarrhythmia and heart failure in fetuses with
congenital heart defects.35 The range of NT-proBNP concentra-
tions obtained from control participants was similar to previous21 vol. 74 j 1087–1096
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-1.5 0-1.0 -0.5 0.5 1.0
Log (fetal bile acid HI), adjusted value
Fetal NT-proBNP concentration vs. fetal
bile acid hydrophobicity index
B
G-conjugated = glycine-conjugated; T-conjugated = taurine-conjugated
r p r p
0.49 0.019 * 0.23 0.232
Unconjugated 0.29 0.187 0.20 0.297
G-conjugated 0.56 0.007** 0.33 0.079
T-conjugated 0.44 0.039* 0.33 0.077
Unconjugated 0.06 0.785 0.12 0.520
G-conjugated 0.19 0.404 0.26 0.179
T-conjugated 0.02 0.931 0.12 0.532
Unconjugated 0.10 0.661 0.05 0.802
G-conjugated -0.36 0.099 -0.05 0.787
T-conjugated -0.04 0.865 0.16 0.397
Unconjugated 0.02 0.914 0.02 0.879
G-conjugated n/a n/a n/a n/a
T-conjugated n/a n/a n/a n/a
Unconjugated -0.26 0.230 -0.02 0.898
G-conjugated -0.33 0.130 0.11 0.572















Fetal NT-proBNP concentration vs.
individual fetal bile acid concentration
Fig. 3. Association between fetal bile acids and NT-proBNP concentrations. (A) Added variable plot of partial correlation analysis between log-transformed
fetal NT-proBNP concentration and fetal bile acid HI measured using umbilical venous blood samples taken from controls (n = 15), untreated ICP (n = 36) and
UDCA-treated ICP (n = 40). (B) Table demonstrating partial correlation analysis of individual fetal serum bile acids and NT-proBNP concentrations from women
with untreated (n = 36) or UDCA-treated (n = 40) ICP only. r = correlation coefficient. Significant p values are presented in bold. *p <0.05, **p <0.01. HI, hydro-
phobicity index; ICP, intrahepatic cholestasis of pregnancy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; UDCA, ursodeoxycholic acid.reports, therefore elevated NT-proBNP concentrations suggest
that ICP fetuses have a cardiac phenotype concordant with
arrhythmic activity and fetal distress.36
Measurement of total and individual serum bile acids in
umbilical venous blood demonstrated that fetal TSBA, GCA and
TCA concentrations and bile acid HI are positively correlated
with fetal NT-proBNP concentrations. This is the first study to
report this association in untreated ICP. GCA and TCA form the
majority of the maternal serum bile acid pool in ICP.37 CA and
TCA administration causes cardiac dysfunction in experimental
models and both are demonstrably deleterious in comparison to
UDCA.29–31,38 This suggests that fetal cardiotoxicity may be an
explanation for the novel finding of a correlation between
elevated NT-proBNP concentration and increased fetal bile acid
HI, an established indicator of bile acid cytotoxicity.27
The association of the severity of fetal cardiac phenotype with
increasing serum concentrations of maternal and/or fetal TSBA is
in agreement with previous studies.11,14,15,19 The severity of
hypercholanemia is associated with adverse fetal outcomes, e.g.
stillbirth when maternal TSBA concentrations exceed 40 lmol/L
and markedly so at >−100 lmol/L.
2–4 No stillbirth events occurred
in our study, although only 3 participants had TSBA concentra-
tions of >−100 lmol/L; 1 untreated fECG study participant had a
TSBA concentration of 187 lmol/L and 2 untreated NT-proBNP
assay participants had TSBA concentrations of 100 lmol/L and
151 lmol/L.
UDCA-treated participants did not have the same fetal cardiac
phenotype as those with untreated ICP. Although the association
between maternal TSBA concentration and PR interval prolon-
gation remained in this cohort, there were no longer associations
between maternal or fetal serum bile acid concentrations and
fHRV parameters or NT-proBNP concentrations. Lack ofJournal of Hepatology 20association between bile acid concentrations and cardiac pa-
rameters in the UDCA-treated cohort may be explained by al-
terations in the fetal bile acid composition and HI, which have
previously been demonstrated in studies of both healthy and
hypercholanemic patients.48,49 The bile acid HI may be of more
relevance than the TSBA concentration, as it is notable that the
TSBA concentrations were not lower in the maternal or fetal
serum samples following UDCA treatment. Consistent with this
observation, UDCA treatment alters the concentration of indi-
vidual bile acids in maternal serum; specifically, the proportion
of UDCA rises from <0.5% to 60% whilst CA reduces from 51% to
<20% in the serum of women with ICP after UDCA treatment.50
Unlike untreated participants, fetal TSBA and GCA concentra-
tions in UDCA-treated participants did not correlate with fetal
NT-proBNP concentrations, which is in line with the calculated
HI and their association with fetal NT-proBNP concentration.
The recent PITCHES trial did not demonstrate an impact of
UDCA treatment on a composite measure of adverse pregnancy
outcome that included stillbirth, preterm birth and neonatal unit
admission.25 This is not contradictory to our data related to an
ICP-associated fetal cardiac phenotype as this study of fECG is of
particular relevance to the etiology of stillbirth. There were 3
stillbirths in the PITCHES trial cohort (2 did not receive UDCA
treatment) from a total of 604 participants.25 Furthermore, 76%
of the 605 PITCHES participants had TSBA concentrations <40
lmol/L, and only 7% participants had concentrations >−100 lmol/L
at the time of randomization.25
The positive correlation between maternal TSBA concentra-
tions and fetal PR interval length is in agreement with previous
studies, although it may not have clinical significance as the
majority of participants had PR interval lengths below estab-
lished thresholds for screening of first-degree atrioventricular21 vol. 74 j 1087–1096 1091
Research Article DILI, Autoimmune, Cholestatic and Genetic Diseases(AV) block.39 Experimental data has demonstrated that bile acid-
induced PR interval prolongation occurs via TCA activation of
muscarinic acetylcholine M2 receptors, resulting in intracellular
calcium dynamic disruption via T-type voltage-dependent cal-
cium channels and slowing of conduction velocity at the AV
node.29,44 This suggests a mechanism by which higher circu-
lating TCA concentrations cause fetal PR interval length prolon-
gation in untreated ICP.
Fetal PR interval prolongation has previously been reported in
both untreated and UDCA-treated cohorts, suggesting that UDCA
treatment is not completely protective.18 PR interval prolonga-
tion was observed in our UDCA-treated cohorts; however, indi-
vidual bile acids were not measured in maternal serum of these
participants and therefore responsiveness to UDCA is unknown.
UDCA has a cardioprotective effect in experimental fetal heart
models.28–31 TCA-induced PR interval prolongation observed in
an in vitro model of the fetal heart was attenuated by UDCA,
although 400 lM of TCA was used which is rarely physiologically
observed in ICP and suggests that UDCA may only be protective
in a subset of women with markedly elevated TSBA concentra-
tions.29 UDCA hyperpolarizes the membrane voltage of in vitro
myofibroblasts via the sulphonylurea receptors, thereby
increasing potassium conductance and counteracting the effects
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Controls and untreated ICP cases
r = 0.43
p = 0.004
Log (maternal TSBA), adjusted value
























Fig. 4. Added variable plots of partial correlation analyses between fetal NT-pr
15) and womenwith untreated ICP (n = 36); (B & E) in womenwith untreated ICP
both controls and cases on the same graph have diamond-shaped data points, plot
with UDCA-treated cases only have circle-shaped hollow data points. ALT, alanin
terminal pro-B-type natriuretic peptide; TSBA, total serum bile acid; UDCA, urso
1092 Journal of Hepatology 20(GPBAR1) in murine ventricular cardiomyocytes although it did
not elicit contractile changes in this cell type.41 Cardioprotective
effects of UDCA in non-cholestatic adults with cardiac disease
have also been reported and serum concentrations of conjugated
UDCA are lower in patients who have had atrial fibrillation
events.28,42,43
The lack of association between maternal TSBA concentra-
tions and fetal QTc interval length is also in agreement with
previous studies.40 Our data has shown a lack of correlation
between maternal TSBA concentrations and maternal ECG pa-
rameters in comparison to control pregnancies. Maternal QTc
interval lengths were found to be within normal range which is
contrary to a previous study using an adult 12-lead ECG device.20
Ideally, diurnal post-prandial fluctuations in TSBA concentrations
and their relationship with fetal cardiac dysfunction would also
be evaluated, but the requirement for hourly venepuncture from
pregnant women and the inability to obtain good quality fECG
data during wakefulness precluded this approach.
The behavioral state of the fetus is indicative of fetal well-
being and is closely associated with fetal movement, FHR and
fHRV.21 This is the first study to our knowledge that investigates
behavioral state-specific time-domain measurements of fHRV in
women with untreated and UDCA-treated ICP. Statistically sig-
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oBNP and maternal TSBA or ALT concentrations. (A & D) In both controls (n =
only (n = 36); (C & F) in womenwith UDCA-treated ICP only (n = 40). Plots with
s with untreated ICP cases only have circle-shaped shaded data points and plots
e aminotransferase; ICP, intrahepatic cholestasis of pregnancy; NT-proBNP, N-
deoxycholic acid.





Fetal PR interval vs. maternal TSBA
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Fig. 5. Association between ICP and PR interval prolongation (A & B) Representative averaged fECG waveforms demonstrating PR interval prolongation (grey)
in untreated severe ICP (C) added variable plot demonstrating the partial correlation between maternal TSBA concentration and fetal PR interval length in both
controls (n = 43) and womenwith untreated ICP (n = 26), (D) in womenwith untreated ICP only (n = 26), (E) in womenwith UDCA-treated ICP only (n = 22). Plots
with both controls and cases have circle-shaped data points, plots with untreated ICP cases only have diamond-shaped shaded data points and plots with UDCA-
treated cases only have diamond-shaped hollow data points. fECG, fetal electrocardiogram; ICP, intrahepatic cholestasis of pregnancy; TSBA, total serum bile acid;
UDCA, ursodeoxycholic acid.(active sleep), likely due to fetuses spending more time in this
behavioral state, resulting in a larger number of data points, as
well as the wider scope of fHRV fluctuation when the fetus is in
an active state.22 Median SDNN and RMSSD values from case
cohorts were within the normal range cited in previous literature
and no infants in our study had clinical indicators of fetal hyp-
oxia at delivery, although there are reports of ICP-induced fetal
hypoxia in other cohorts.45–47
A limitation of this study is the fact that the UDCA-treated
and untreated participants were not matched for severity of
hypercholanemia. In future, if it were feasible to study a pro-
spectively recruited cohort of untreated vs. UDCA-treated
women with TSBA concentrations of >−100 lmol/L, one could
confirm the association between fetal cardiac function and
highly elevated TSBA concentrations. The optimal experimental
design would have taken both umbilical venous blood and fECG
samples from the same participants to avoid differences in de-
mographic data between severe ICP cohorts. Additionally, data
on the duration of delivery would also be collected as part of
multivariate statistical analysis of fetal NT-proBNP concentra-
tions. To eliminate the potential effect of individual differences in
HRV, this study should be repeated with a larger cohort of ICP
participants prior to and after UDCA treatment with respon-
siveness to the drug also assessed.
Conclusion
This study has demonstrated a fetal cardiac phenotype that is
associated with severity of ICP in untreated pregnancies.
Although further investigation is required to assess the impactJournal of Hepatology 20and importance of these anomalies, these data provide a step
towards understanding the mechanisms of ICP-associated fetal
cardiac pathologies and support the hypothesis that elevated
circulating fetal bile acids may predispose the fetal heart to a
sudden arrhythmic event. Further studies measuring fetal car-
diac parameters in a larger cohort, particularly in women who
have serum bile acid concentrations >−100 lmol/L, are required to
establish the risk of elevated serum bile acid concentrations, to
stratify those who would benefit most from increased fetal heart
monitoring, and to clarify whether UDCA treatment is protective
for these high-risk pregnancies.
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Fig. 6. Association between untreated ICP and fetal heart rate variability (A-D) Added variable plots demonstrating the partial correlation between maternal
TSBA concentration and fetal heart rate variability measurements in controls (n = 16 in 1F and n = 33 in 2F) and untreated ICP (n = 13 in 1F and n = 36 in 2F).
RMSSD data points are triangles whilst SDNN data points are squares. (E-H) Box and whisker plots demonstrating the medians and IQRs of fetal heart rate
variability measurements of controls (n = 16 in 1F and n = 33 in 2F), untreated ICP (n = 13 in 1F and n = 36 in 2F) and UDCA-treated ICP (n = 15 in 1F and n = 20 in
2F). Analysis via Kruskal Wallis test with post-hoc Dunn's. *p <0.05, **p <0.01. ICP, intrahepatic cholestasis of pregnancy; RMSSD, root mean square of successive
differences; SDNN, standard deviation of normal to normal intervals; TSBA, total serum bile acid; UDCA, ursodeoxycholic acid.
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